Pharmacokinetics and Pharmacodynamics of Nasally Applied Esketamine

The purpose of this study is the determination of blood concentration and the effectiveness of esketamine after nasal application.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pain Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Clinical Research Center, University Hospital Basel

Basel, Canton of Basel-City, 4031, Switzerland

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

male
age ≥18 years ≤ 45 years
healthy
non-smoking
BMI 18-27

Exclusion criteria

abuse of drugs
known or supposed hypersensitivity and/or contraindication against ketamine or additives
participation of another clinical study within the last 30 days
chronic obstructed nose breathing or nasal polyps
dug allergy
blood donation within the last two months

Treatment and study plan

Esketamine hydrochloride

Drug

Sponsors and collaborators

Lead sponsor

University Hospital, Basel, Switzerland

Other

Registry information

Important dates

Study start: 2009
Study completion: 2009
First posted: Feb 19, 2009
Registry last updated: Dec 2, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed